Latest From Immunomedics Inc.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
Keeping Track Of Approvals: US FDA Keeps Up Fast Pace In Oncology With Early Nods For Trodelvy, Pemazyre
The latest US FDA product approval news from the Pink Sheet FDA Performance Tracker.
Trodelvy was granted an accelerated approval by the US FDA based on a Phase II study. It is the first commercial product for Immunomedics.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
- Large Molecule
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Immunomedics Inc.
- Senior Management
Usama Malik, CFO & CBO
Brendan Delaney, Chief Commercial Officer
Morris Rosenberg, CTO
- Contact Info
Phone: (973) 605-8200
300 The American Rd.
Morris Plains, NJ 07950